Australia's most trusted
source of pharma news
Posted 24 November 2021 AM
It's been a year of disappointment for some Australian pharmas with 14 major drugs either rejected or deferred by PBAC so far in 2021, with the fate of another four from November's meeting, hanging in the balance.
An analysis by Pharma in Focus examined "new listing" submissions made to the committee's meetings in March, May, July and September and considered drugs which were resubmitted to the PBAC's last major meeting of the year, and its upcoming intracycle meeting in December.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.